๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease

โœ Scribed by Zhang, Danhui; Bordia, Tanuja; McGregor, Matthew; McIntosh, J. Michael; Decker, Michael W.; Quik, Maryka

Book ID
125432562
Publisher
John Wiley and Sons
Year
2014
Tongue
English
Weight
848 KB
Volume
29
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Topiramate reduces levodopa-induced dysk
Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease
โœ Monty A. Silverdale; S.L. Nicholson; A.R. Crossman; J.M. Brotchie ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 87 KB ๐Ÿ‘ 1 views

## Abstract Overactive AMPA receptorโ€mediated transmission may be involved in the pathogenesis of levodopaโ€induced dyskinesia. The mechanism of action of the anticonvulsant drug topiramate involves attenuation of AMPA receptorโ€mediated transmission. In this study, the potential antidyskinetic actio

Stimulation of cannabinoid receptors red
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease
โœ Susan H. Fox; Brian Henry; Michael Hill; Alan Crossman; Jonathan Brotchie ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 291 KB ๐Ÿ‘ 1 views

Long-term treatment with levodopa in Parkinson's disease results in the development of motor fluctuations, including reduced duration of antiparkinsonian action and involuntary movements, i.e., levodopa-induced dyskinesia. Cannabinoid receptors are concentrated in the basal ganglia, and stimulation

Genotype and smoking history affect risk
Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease
โœ Judith A. Strong; Arif Dalvi; Fredy J. Revilla; Alok Sahay; Frederick J. Samaha; ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 112 KB ๐Ÿ‘ 1 views

Parkinson's disease (PD) patients vary widely in their response to levodopa treatment, and this variation may be partially genetic in origin. We determined whether particular dopamine and opioid receptor polymorphisms were associated with risk of earlier onset of dyskinesia side effects during levod